New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2

A regimen of busulfan and cyclophosphamide (BuCy2) is regarded as the standard myeloablative regimen for SCT. This study evaluated the hypothesis that fludarabine can replace cyclophosphamide for myeloablative allogeneic SCT. Ninety-five patients underwent allogeneic SCT from HLA-identical donors, f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2007-09, Vol.40 (6), p.541-547
Hauptverfasser:	CHAE, Y. S, SOHN, S. K, KIM, Y.-K, KIM, H.-J, KIM, J. G, CHO, Y. Y, MOON, J. H, SHIN, H. J, CHUNG, J. S, CHO, G. J, YANG, D. H, LEE, J.-J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Arterial Occlusive Diseases - chemically induced Arterial Occlusive Diseases - mortality Biological and medical sciences Bone marrow Bone marrow, stem cells transplantation. Graft versus host reaction Busulfan Busulfan - administration & dosage Busulfan - adverse effects Conditioning Confidence intervals Cyclophosphamide Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Cytomegalovirus Infections - mortality Development and progression Disease-Free Survival Dosage and administration Female Fludarabine Graft versus host reaction Graft vs Host Disease - mortality Health risks Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - mortality Histocompatibility antigen HLA Humans Incidence Leukemia - mortality Leukemia - therapy Male Medical sciences Middle Aged Myeloablative Agonists - administration & dosage Myeloablative Agonists - adverse effects Patient outcomes Prophylaxis Recurrence Retrospective Studies Risk analysis Risk Factors Stem cell transplantation Stem cells Survival Survival Rate Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation Conditioning - adverse effects Transplantation Conditioning - methods Transplantation, Homologous Vidarabine - administration & dosage Vidarabine - adverse effects Vidarabine - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A regimen of busulfan and cyclophosphamide (BuCy2) is regarded as the standard myeloablative regimen for SCT. This study evaluated the hypothesis that fludarabine can replace cyclophosphamide for myeloablative allogeneic SCT. Ninety-five patients underwent allogeneic SCT from HLA-identical donors, following BuCy2 (n=55) or busulfan+fludarabine (BF, n=40). The efficacy of fludarabine compared to cyclophosphamide was retrospectively evaluated. The BF group exhibited a shorter duration until engraftment (P=0.001), lower incidence of acute and chronic GVHD (P
ISSN:	0268-3369 1476-5365
DOI:	10.1038/sj.bmt.1705770